Nasopharyngeal Carcinoma Clinical Trial
Official title:
Far Eastern Memorial Hospital
| Verified date | September 2011 |
| Source | Far Eastern Memorial Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Taiwan: Department of Health |
| Study type | Observational |
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in southern China
and Southeast Asia. While infection with Epstein-Barr Virus (EBV) is believed to be
necessary for the development of NPC, non-viral environmental factors have also been
implicated to increase the risk of NPC including consumption of salted fish and other
nitrosamine containing preserved foods, formaldehyde and wood dust exposure, and cigarette
smoking. In addition to environmental factors, it is widely accepted that genetic
susceptibility also plays an important role in the pathogenesis of NPC. Polymorphisms in
genes involved in nitrosamine metabolism and DNA repair have been suggested to be associated
with NPC risk, and various chromosomal regions linked to NPC development have been reported.
These associations highlight the role of both environmental and genomic components in the
etiology of NPC.
There is a longstanding history of international collaborative studies to elucidate the role
of environmental and genetic factors associated with NPC between investigators in Taiwan and
the USA. A case-control study (375 cases; 327 controls) was conducted in the early 1990s,
and a large multiplex family study that was completed in 2006 (358 families; 3,216
individuals). Results from these studies have provided some of the most comprehensive
epidemiological evidence regarding factors linked to NPC development to date.
As a next logical step, the opportunity now exists to undertake a genome-wide association
study of NPC in Taiwan with carefully collected environmental exposure data to
systematically examine environmental and genetic factors associated with NPC, and to
evaluate gene-gene and gene-environment interactions. The investigators propose a
case-control study of 2000 NPC cases (both retrospective [n=800] and prospective [n=1,200])
and 2,000 age-gender-matched hospital controls in northern Taiwan. The study objectives are
to: 1) evaluate putative environmental exposures and NPC; 2) assess the effect of genetic
factors, including both single nucleotide polymorphism and copy number variation through
analysis of both main effect and gene-gene interaction; 3) investigate gene-environment
interactions by testing for interactions between significant genome-wide genetic variations
and EBV and other identified environmental risk factors; and 4) examine the natural history
of EBV infection.
| Status | Recruiting |
| Enrollment | 4000 |
| Est. completion date | December 2014 |
| Est. primary completion date | December 2014 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients diagnosed with NPC Exclusion Criteria: - Case group and control group younger than 18 age. Control group, the reasons for hospitalization for the EB virus-related disease |
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | Far Eastern Memorial Hospital | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| Far Eastern Memorial Hospital | National Taiwan University Hospital |
Taiwan,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05979961 -
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT06055816 -
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05547971 -
Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
|
||
| Not yet recruiting |
NCT05020925 -
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04548271 -
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04547088 -
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02795169 -
Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02569788 -
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02801487 -
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02237924 -
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02044562 -
Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
|
N/A | |
| Terminated |
NCT01694576 -
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
|
Phase 2 | |
| Recruiting |
NCT01462903 -
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01271439 -
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT00535795 -
Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA
|
Phase 3 | |
| Completed |
NCT00379262 -
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
|
Phase 3 | |
| Completed |
NCT03398980 -
Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy
|
N/A | |
| Completed |
NCT01309633 -
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
|
Phase 2 |